I subscribe to a number of journals.

New England Journal of Medicine

From Vaccine Nationalism to Vaccine Equity — Finding a Path Forward
New England Journal of Medicine, Volume 384, Issue 14, Page 1281-1283, April 2021.
>> Read more

Vancomycin Infusion Reaction — Moving beyond “Red Man Syndrome”
New England Journal of Medicine, Volume 384, Issue 14, Page 1283-1286, April 2021.
>> Read more

Beyond the Rubble of Lake Street — Minds in Crisis in a City in Crisis
New England Journal of Medicine, Volume 384, Issue 14, Page 1286-1287, April 2021.
>> Read more

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
New England Journal of Medicine, Volume 384, Issue 14, Page 1289-1300, April 2021.
>> Read more


Heartbeat: racial and ethnic healthcare disparities in cardiovascular care
Racial and ethnic healthcare disparities in cardiovascular care have been magnified during the COVID-19 pandemic. In this issue of Heart, Rashid and colleagues1 compared admission rates, treatment and mortality of black, Asian and minority ethnic (BAME) patients with acute myocardial infarction (AMI) in England in 2020 compared with the 3 previous years. Compared with white patients, a higher proportion of BAME patients were hospitalised with AMI during the pandemic (figure 1). However, in those with AMI, BAME patients less often underwent coronary angiography (86.1% vs 90.0%, p<0.001), had a longer median delay to reperfusion (4.1 hours vs 3.7 hours, p<0.001) and a higher in-hospital (OR 1.68, 95% CI 1.27 to 2.28) and 7- day mortality (OR 1.81 95% CI 1.31 to 2.19). Figure 1 Time series plot of daily proportions of BAME patients hospitalised with diagnosis of AMI from 1 January 2017 to 27 May 2020...
>> Read more

Natriuretic peptides in atrial fibrillation: evidence is here, but are we ready to go one step beyond?
When making a diagnosis of atrial fibrillation (AF), we are all of a sudden flagging our patient with an increased risk of stroke, heart failure and death. Then, we aim at preventing these complications and improving the quality of life of our patient, but our chances of success will largely depend on the availability of safe and effective treatments and on our ability to accurately identify those patients at the highest risk. Anticoagulants have been used for more than six decades, and heparins and vitamin K antagonists were early found to prevent thromboembolic events. In the absence of other therapeutic options, the prognostic evaluation of patients with AF has been largely, almost exclusively, limited to the thromboembolic risk assessment. However, even after proper anticoagulation, patients with AF remain at a high risk of death and hospitalisation.1 Early epidemiological studies had already demonstrated that AF independently associates with...
>> Read more


Heart Rhythm